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Studies reveal that 10-27% of older adults chronically use anticholinergic medications.           
Increased cumulative anticholinergic burden scores are associated with increased risks of           
dementia. The mechanisms by which anticholinergic drugs negatively impact cognition remain           
elusive. However, researchers speculate that the drug’s impairment of cholinergic neurons           
promotes neuroinflammation. 
Research question or Hypothesis 
We hypothesize that drugs with anticholinergic properties will induce inflammation in the brain.              
MCP1 and IL 6 are chemokines that contribute to neuroinflammation. We investigated the             
influence of diphenhydramine (Benadryl) on the production of MCP1 and IL-6 in Normal Human              
Astrocytes and Paroxetine on the production of MCP1 in Normal Human Astrocytes and Normal              
Human Brain Microvascular Endothelial Cells. 
Methods 
Normal Human Astrocytes were cultured (seeded at 5,000 cells/cm2) and treated with a             
clinically relevant concentration (equivalent to clinically observed Cmax for the respective drugs)            
of diphenhydramine (​66ng/ml​) and Paroxetine (​1.67*10​-4​mM). ​RNA was isolated and converted           
into cDNA, and then gene expression was measured via RT-PCR. MCP1 and IL-6 protein              
production were measured from cell culture supernatants by ELISA. One-way ANOVA           
compared MCP-1 and IL-6 protein concentrations with Tukey correction for multiple corrections.            
The gene expression was reported with relative significance (p= 0.05) using Student’s t-test. 
14 
 
 
 
Conclusions 
Drugs with anticholinergic properties are considered to be pro-inflammatory. However, our data             
from normal human astrocytes treated suggest that diphenhydramine possesses         
anti-inflammatory properties. This preliminary finding suggests the possibility of pathological          
mechanisms of anticholinergic medications with dementia that may not be associated with            
inflammation.  
Our data from Paroxetine in normal human brain microvascular endothelial cells suggest that             
Paroxetine possesses pro-inflammatory properties. Our preliminary findings indicate the         
possibility of a pathological pro-inflammatory mechanism associated with Paroxetine. Further          
evaluation of anticholinergic drugs in the human brain is warranted.  
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1. INTRODUCTION  
In the 20th century, astonishing population growth was aging in the United States. In 1900, 3.1                
million Americans were 65 years and older, representing 4% of the total population. According              
to the Census Bureau, in 1986, the population had grown to 29.2 million persons or 12.1% of                 
the total population. The population projections of the 21st century still indicate the continuation              
of growth. Those 85 years and older are the most rapidly growing population in terms of actual                 
numbers and percentages of the total population. Concurring to the Social Security            
Administration, the number of individuals at or above age 65 is expected to rise from thirty-four                
million in 1995 to eighty-seven million in 2080. Whereas, the population at or above age               
eighty-five is expected to grow from 3.8 million in 1995 to 18.3 million in 2080. ​(Biology of Aging-                  
Handbook) 
1.1 AGING 
Aging is the process of growing older. It is a gradual, continuous, and complex process               
associated with dynamic biological, physiological, psychological, and behavioral changes. Even          
though aging is associated with mild changes such as graying of hair, some significant              
age-related changes can decline daily-life activities and increase vulnerability to various           
diseases, frailty, and disability. Aging is a substantial chance for many acute and chronic              
conditions, including neurodegenerative disease. There is no single principle to explain aging.            
However, studies have shown that aging can be slowed, suggesting that we can delay the               
appearance or reduce the number of diseases and increase older adults’ health span by aiming               
for aging. Researchers are presently centering on hereditary, natural life-style, behavioral and            
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social components, and their effect on the initiation and progression of age-related diseases and              
neurodegenerative conditions. ​(www.nia.nih.gov​) 
1.2 COMPLEXITY OF AGING 
More than 248 million of roughly 418 million people aged 65 years and over (59%) now reside in                  
the developing countries. The world’s elderly distribution will be shifting considerably in the             
upcoming decades, with a growing proportion of 67% by 2020. ​Asia has the first noteworthy               
number of older adults, 217 million. China alone has 87 million people (6.8 percent of its                
populace) aged sixty-five year and older, and this will increment to 167 million (11.5 percent) by                
2020.​1 
With advancing age, there is an increased vulnerability to chronic health problems. New             
diagnoses will further add complexity to the health status of older adults with pre-existing health               
problems. Many health disorders experienced by older individuals are commonly managed with            
medications. Antibiotics, cardiovascular, psychotropics, anticholinergics are used routinely to         
treat health disorders observed in older adults. However, drug development clinical trials often             
exclude older adults. ​2 A survey conducted in Australia, New Zealand, Canada, United             
Kingdom, and the United States, showed that approximately 75% of those aged 65 took at least                
one prescription drug regularly for chronic medical conditions. ​3 
Multimorbidity that increases with social deprivation and age is also associated with functional             
decline, more reduced quality of life, increased mortality, and significantly more healthcare            
usage. Multimorbidity is characterized by two or more chronic conditions that cannot be cured              
and are controlled through medications and other treatments. ​7 
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The prevalence of polypharmacy is also common in this segment of the population.             
Polypharmacy defined as prescribing a threshold of five to seven medications or more.             
Inappropriate medication use, improper drug use, inappropriate prescribing, potentially         
inappropriate prescription are the terms used to recognize under-prescribing, over-prescribing,          
and mis-prescribing practices ​4​. Multiple cohort studies have recently reported increased,           
potentially inappropriate medicines in acute and long-term settings in community-dwelling older           
people. Furthermore, these studies revealed associations between inappropriate medications         
and increased risks of adverse drug reactions, morbidity, and mortality. ​5 The use of multiple               
medicines, especially with high anticholinergic properties in older adults, leads to increased            
cognitive function risks, impaired judgment, and a decline in intellectual understanding. During            
the hospital stay, older adults with cognitive impairment are also at an increased risk of delirium,                
resulting in extended hospital stays and increased thirty-day mortality rates. ​6 
Although drug therapy is considered central in most chronic medical conditions experienced by             
older adults, a substantial number of these individuals also experience adverse drug reactions             
(ADR). ADRs are a severe health problem, and it is reported that older adults are seven times                 
more likely than younger adults to have ADRs that require hospitalization. The number of              
prescription drugs is the primary indicator of risk for an adverse drug reaction. As the number of                 
prescriptions increases in older adults, the odds of an adverse drug reaction, especially             
cognitive impairment, are increased. ​8 Cognitive impairment (CI), in older people, is broadly             
definable ADR. Some drugs are associated with increased risks of depression, suicide,            
seizures, and confusion. These symptoms are more challenging to assess and can impact the              
cognitive abilities of older adults.  
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Drugs with anticholinergic properties are prescribed widely to older adults, but adverse effects             
often restrict their use. Many commonly used medications, such as digoxin, psychotropics, and             
anticholinergic (muscarinic-blocking) properties, have been consistently associated with        
increased cognitive impairment risks. Several alterations in intrinsic physiological factors, such           
as pharmacokinetics and pharmacodynamics changes, also put older adults at increased           
chances of developing cognitive impairment from medications. ​2 
2. TOOLS TO ASSESS QUALITY OF GERIATRIC CARE 
In recent years, several criteria have been developed to classify medication usage’s            
appropriateness while protecting older adults from adverse events. The Beer’s criteria,           
Screening Tool of Older Persons Prescription (STOPP), and Screening Tools to Alert Doctors             
To Right Treatment (START) are the best known and widely studied in the US and Europe. ​9  
2.1 BEER’S CRITERIA 
The American Geriatrics Society (AGS) Beer’s criteria for Potentially Inappropriate Medication           
(PIM) Use in Older Adults is utilized broadly by clinicians, educators, researchers, healthcare             
administrators, and regulators. The AGS Beers Criteria is a list of potentially inappropriate             
medications that should be avoided by older adults in most cases or under specific situations,               
such as in certain diseases or conditions. The five types of criteria in the 2019 updated Beers                 
criteria include:  
1. Medications that are potentially inappropriate in most older adults. 
2. Those that should typically be avoided in older adults with certain conditions. 
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3.  Drugs to use with caution.  
4. Drug-drug interactions. 
5. Drug dose adjustment based on kidney function. 
The Beers criteria are considered for use in adults 65 years and older in all ambulatory, acute,                 
and traditional care settings, except for the hospice and palliative care settings. To improve              
medication selection, educate clinicians and patients, reduce adverse drug events, and serve as             
a tool for evaluating the quality of care, cost, and drug use patterns of older adults. The primary                  
objective of the 2019 update proceeds to be improving the care of older adults by diminishing                
their exposure to Potentially Inappropriate Medications (www.americangeriatrics.org). 
3. LITERATURE REVIEW 
Several investigators have reported the use of anticholinergics associated with sustained           
cognitive defects in older adults. A prospective population-based cohort study was conducted to             
examine if cumulative anticholinergic use is associated with an increased risk for incident             
dementia. The researchers used data from the Adult Changes in Thought study in Group              
Health. The study included 3434 participants aged 65 or older with no dementia. The most               
anticholinergic classes used were tricyclic antidepressants, first-generation antihistamines, and         
bladder antimuscarinics. They observed that during the mean follow-up of 4.8 years, 23.2%             
developed dementia, whereas,79.9% considered to have possible Alzheimer’s disease (AD). ​10 
A longitudinal study was conducted between 2 cohorts (participants taking medium or high             
anticholinergic medications compared to those not taking these medications) to determine the            
association between anticholinergic medications use and cognition, glucose metabolism and          
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brain atrophy in cognitively healthy older adults from the Alzheimer’s Disease Neuroimaging            
Initiative (ADNI) and Indiana Memory and Aging Study (IMAS). They found that medications with              
medium or high anticholinergic activity were associated with imperfect memory, brain           
hypometabolism, brain atrophy, and increased cognitive impairment risk. This study was the first             
to examine the in vivo brain structural and functional differences. ​11 
Selective Serotonin Reuptake Inhibitors, including Fluoxetine, Paroxetine, Citalopram,        
Sertraline, Escitalopram is the most prescribed type of antidepressants. But little is known if              
there is a connection between depression and dementia. A prospective cohort study was             
conducted in community-dwelling individuals aged 65 years and older adults without dementia,            
to determine if antidepressants (serotonin reuptake inhibitor- Paroxetine, tricyclic         
antidepressants, serotonin antagonist and reuptake inhibitors) use was associated with          
increased risks of dementia. The findings concluded that 25% of the participants developed             
dementia, whereas 22% developed possible Alzheimer’s disease. Paroxetine was found to be            
most associated with increased dementia risk. ​12 
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4. ANTICHOLINERGICS 
A vast number of medications on the updated (2019) Beer’s list are considered potentially              
inappropriate due to their anticholinergic properties. Older adults subjected to increased           
anticholinergic load due to the extensive use of anticholinergic/antimuscarinic medications and           
the medications with anticholinergic side effects (antihistamine, antidepressants, skeletal         
muscle relaxant, antipsychotics, antispasmodic). Older adults widely use anticholinergics         
medications as an OTC or as a prescription for diverse conditions such as seasonal allergies,               
overactive bladder, and depression. The predominance of anticholinergic use in older adults            
ranges from 8-37%. ​13 The risks may outweigh the benefits of using anticholinergics in older               
adults. Well-known chances of anticholinergic burden are falls, worsened functioning, and           
worsened cognition. Older adults are more sensitive to anticholinergic effects due to            
pharmacokinetic and pharmacodynamic changes, diminished acetylcholine transmission in the         
brain, and increased permeability of the blood-brain barrier. It is suspected that the cognitive              
impairment associated with these agents can be reversible on the medications’ discontinuation.            
Several investigators have still reported that the anticholinergics can be related to sustained             
cognitive defects such as mild cognitive impairment or dementia. ​10 
4.1 ANTICHOLINERGIC BURDEN LIST  
Anticholinergic medications are classified on an anticholinergic burden list. The ACB list has             
been previously used to identify cognitive impairment risks in many populations using            
anticholinergic drugs. The Anticholinergic Cognitive Burden List identifies anticholinergics with          
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varying degrees of anticholinergic activities. Medications on the Anticholinergic Cognitive          
Burden list are classified into two groups: 
1. Medications with possible anticholinergic effects: those with ​in-vitro ​anticholinergic         
activity with no reported evidence of clinical anticholinergic properties. 
2. Medications with definite anticholinergic activity: those with functional and clinically          
relevant effects on cholinergic signaling. ​6 
It is recommended that clinicians, pharmacists, and healthcare professionals consider the           
anticholinergic properties of medications when adding or changing the patient's drug regimen to             
minimize the anticholinergic side effects ( Rochon, Paula., 2020) 
4.2 MECHANISM OF ACTION OF ANTICHOLINERGICS 
Generally, anticholinergics produce their effects by blocking acetylcholine (Ach), which acts as a             
neurotransmitter at the presynaptic terminal at the central and peripheral nervous system. They             
inhibit the parasympathetic nerve impulses by selectively blocking the binding of acetylcholine to             
nerve cells. Apart from producing therapeutic effects, some anticholinergics produce some           
therapeutic results that are not primary therapeutic effects. The mechanism by which they             
produce these effects is still unknown, but researchers have speculated that the cholinergic             
neuron’s direct impairment may underlie these effects. ​10 
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5. THE CHOLINERGIC ANTI-INFLAMMATORY  PATHWAY 
The inflammatory reflex is stimulated when the afferent vagus nerve senses the inflammatory             
products such as cytokines, damage-associated pathogen patterns through the cytokine          
receptor, and pattern recognition receptors. The nerve activity is transfer through the central             
nervous system (CNS) to the efferent vagus nerve. The first pathway involves the splenic nerve,               
a coordinate association between the afferent vagus nerve and splenic nerve is still debatable.              
Triggered splenic nerves release norepinephrine from their terminals, which interacts with           
β2-adrenergic receptors, expressed on the choline acetyltransferase (ChAT)-positive T cells          
within the spleen, causing the release of acetylcholine (ACh) for specific T cell. Acetylcholine              
binds to α7 nicotinic acetylcholine receptors (α7nAChRs) expressed on macrophages, resulting           
in suppressing proinflammatory cytokine production by macrophages.​14 
5.1 HYPOTHESIS 
Cholinergic signaling is anti-inflammatory; we are hypothesizing that anticholinergic medications          
will induce inflammation in the brain. 
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6. SPECIFIC AIMS 
1. To characterize the effect of Diphenhydramine on the physiological and          
pathophysiological properties of normal human astrocytes. 
2. To characterize the effects of Paroxetine on the physiological and pathophysiological           
properties on normal human astrocytes. 
3. To characterize the effects of Paroxetine on the physiological and pathophysiological           
properties on normal human brain microvascular endothelial cells. 
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7. DIPHENHYDRAMINE 
Diphenhydramine hydrochloride is an antihistamine drug with a chemical name of           
2-(diphenylmethane)-N, N -dimethyl ethylamine hydrochloride with a molecular formula C 17H           
21NO•HCI (molecular weight 291.82) (​www.accessdata.fda.gov) 
7.1 PHYSICOCHEMICAL PROPERTIES  
It occurs as a white odorless, crystalline powder and soluble in water and alcohol.  
7.2 DOSAGE 
Adults: ​25 to 50 mg, three or four times daily.  
The nighttime sleep-aid dosage is 50 mg at bedtime​. 
7.3 STORAGE 
Keep tightly closed—store at 20° to 25°C (68° to 77°F). Protect from freezing and light. 
7.4 PHARMACOLOGY OF DIPHENHYDRAMINE 
Diphenhydramine hydrochloride is an antihistamine with anticholinergic and sedative effects.          
Diphenhydramine (Benadryl) is a first-generation H1 antagonist that acts as a reversible            
competitive inhibitor of histamine, which binds to the H1 receptor.  
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7.5 USAGE 
Diphenhydramine hydrochloride is used to relieve runny nose, itching of the nose or throat, and               
itchy, watery eyes from hay fever or upper respiratory allergies, for active and prophylactic              
treatment of motion sickness and nighttime sleep aid. 
7.6 PHARMACOKINETICS OF DIPHENHYDRAMINE 
Diphenhydramine pharmacokinetics in adults for single doses of 25 and 50 mg            
diphenhydramine HCl have been reported in several studies. Following the intravenous           
administration of 50 mg, diphenhydramine is observed at a maximum concentration of 66ng/ml             
(concentration used in the experiments to treat the normal human astrocytes and normal human              
brain microvascular endothelial cells). Diphenhydramine’s total systemic clearance is 6.16          
mL/min/kg, the volume of distribution is 4.54 L/kg, and its exponential half-life is 8.5 hours.               
Following oral administration of 50 mg in studies conducted, diphenhydramine attained           
maximum concentrations at 2.3 and 2.2 hours and had exponential half-lives of 9.2 and 9.8               
hours. Diphenhydramine undergoes the first-pass metabolism after oral administration with an           
absolute bioavailability of 72% ± 8%, with about 2% of the dose remaining unchanged in the                
urine. Diphenhydramine is metabolized via demethylation to N-demethyl diphenhydramine,         
which is demethylated to N, N-didemethyl diphenhydramine further metabolized by oxidative           
deamination to diphenylmethoxyacetic acid. The initial N-demethylation has not been reported           
to be related to cytochrome p450 2D6 (CYP2D6) activity. Still, the subsequent N-demethylation             
has reduced in subjects who were phenotype as CYP2D6 poor metabolizers. In drug-interaction             
pharmacokinetic studies with venlafaxine and metoprolol, diphenhydramine was shown to be an            
inhibitor of CYP2D6 ​15 
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8. NORMAL HUMAN ASTROCYTES 
Michael von Lenhossék introduced the term astrocyte (Astron, star, and kytos, a hollow vessel,              
later cell, i.e., star-like cell) in 1895. Astroglia belongs to a class of neural cells (also known as                  
astrocytes) of ectodermal, neuroepithelial origin that maintain homeostasis and provide a           
defense of the central nervous system (CNS). Astrocytes are highly diverse in form and function               
and exhibit high adaptive plasticity, which helps in functional maintenance of the CNS in              
development and aging. Astrocytes are involved in controlling homeostasis of the CNS at all              
levels of the organization. Through transporting the significant ions and protons, removing and             
catabolizing neurotransmitters, releasing neurotransmitter precursors, and scavengers of        
reactive oxygen species, astrocytes maintain the molecular homeostasis. Astrocytes are also           
involved in supporting the neurotransmission and controlling cellular homeostasis through          
embryonic neurogenesis (that occurs from radial glia) and adult neurogenesis (which includes            
stem astrocytes of neurogenic niches). By synthesizing glycogen and supplying neurons with            
energy substrates, astrocytes regulate the metabolic homeostasis.​16 
9. CHEMOKINES (MCP-1) AND CYTOKINE (IL- 6) 
Chemokines are small heparin-binding proteins that constitute a large family of peptides            
(60–100 amino acids) related to cytokines structurally. The primary function is to regulate cell              
trafficking. Chemokines can be classified into four subfamilies based on the number and             
location of the cysteine residues at the N-terminus of the molecule and are named CXC, CC,                
CX3C, and C. The structure of chemokines is composed of three distinct domains: (1) a highly                
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flexible N-terminal domain, which is constrained by disulfide bonding between the N-terminal            
cysteine, (2) a long loop that leads into three antiparallel β-pleated sheets; and (3) an α-helix                
that overlies the layers. Chemokines are divided into two main functional subfamilies:            
inflammatory and homeostatic chemokines. Inflammatory chemokines control the recruitment of          
leukocytes in inflammation and tissue injury, whereas, homeostatic chemokines attain          
housekeeping functions such as navigating leukocytes to and within secondary lymphoid organs            
and the bone marrow and the thymus during hematopoiesis. 
Chemokines induce chemotaxis by activating G-protein-coupled receptors (GPCRs), including         
adhesion molecules and glycosaminoglycans (GAGs). Chemokines bind to specific cell surface           
transmembrane receptors coupled with heterotrimeric G proteins, which leads to the activation            
of intracellular signaling cascades, which further causes the migration towards chemokines. 
The monocyte chemoattractant protein-1 (MCP-1/CCL2) is a member of the C-C chemokine            
family and a potent chemotactic factor for monocytes. Located on chromosome 17 (chr.17,             
q11.2​), human MCP-1 is composed of 76 amino acids. MCP comprises four members (MCP-1,              
−2, −3, and −4). CCL2 is produced by various cell types, either by oxidative stress, cytokines, or                 
growth factors. CCL2 is produced by many cell types, such as endothelial, fibroblasts, epithelial,              
smooth muscle, mesangial, astrocytic, monocytic, and microglial cells. CCL2 regulates          
monocytes migration and infiltration, memory T lymphocytes, and natural killer (NK) cells. ​18 
Cytokines are small proteins, Interleukin-6 (IL-6) is a cytokine which induces the maturation of B               
cells into antibody-producing cells. The essential sources of IL-6 in the CNS are neurons,              
astrocytes, microglia, and endothelial cells. IL-6 participates in neurogenesis, influencing both           
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neurons and glial cells, oligodendrogliogenesis, and astrogliogenesis. IL-6 is a prototypical           
four-helix bundle cytokine. ​19 
 
10. NEURODEGENERATIVE GENES 
Glutamate is the major excitatory neurotransmitter of the nervous system and is involved in              
memory and neuronal activity. In neuronal death, the overstimulation of glutamate has been             
reported. There are two forms of glutamate receptors, ionotropic and metabotropic.           
Metabotropic glutamate receptors (mGluRs) have eight subtypes so far. They are divided into             
subgroups (Group I: mGluR1 and mGluR5, Group II: mGluR2 and mGluR3 and Group III:              
mGluR4, mGluR6, mGluR7, and mGluR8) based on cell signaling activation and sequence            
homology. Metabotropic glutamate receptors are G protein-coupled receptors and are widely           
spread in the central nervous system and implicated in various neurodegenerative diseases,            
including Alzheimer’s disease and Parkinson and Huntington’s disease. Elevated levels of           
mGluR1 have been found in the neurons of the olfactory bulb, cerebellar cortex, ventral              
pallidum, globus pallidus, entopeduncular nucleus, lateral septum, magnocellular preoptic         
nucleus, and thalamic nuclei.​57 The widespread presence was also reported in cerebellar            
Purkinje cells. Group, I mGluR expression has been observed in the substantia nigra, globus              
pallidus, lateral septum, and thalamic relay nuclei.​58 
CREB signaling has also been reported for long-lasting changes in synaptic plasticity and             
further mediates short-term memory conversion to long-term memory. CREB signaling has been            
implicated in several brain pathological conditions, including cognitive and neurodegenerative          
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disorders. The β-amyloid (Aβ) peptide, which plays a crucial part in Alzheimer’s disease’s             
pathogenesis, also alters the hippocampal-dependent synaptic plasticity and memory and          
mediates the synapse loss through CREB signaling pathway. Alteration in CREB signaling has             
been associated with other cognitive disorders, including Huntington’s disease and          
Rubinstein-Taybi and Coffin-Lowry syndromes suggesting an essential role of CREB signaling           
in cognitive dysfunction.​59 
Mitochondria are essential organelles for energy metabolism and are critical for adaptation to             
oxidative stress, calcium homeostasis, and cellular viability and function regulation.          
Mitochondrial dysfunction in many psychiatric disorders has been reported in many           
neuroimaging, GWAS, and postpartum brain analysis. Mitochondrial impairment can increase          
the production of reactive oxygen species, altering the cellular functions. The accumulation of             
oxidative damage in the brain results in the loss of neuronal plasticity and function. Several               
GWAS studies have identified CACNA1C as one of the relevant genetic risk factors for              
developing bipolar disorder and major depressive disorder.​60 
An explorative gene expression analysis will be performed to find the drug’s unexplained effect              
on the brain. We are interested in seeing if drugs with high anticholinergic properties modulate               
any genes that are already associated with neurodegeneration. We are focusing on adverse             
drug reactions or how the mechanism of the ADR happens so if there is any genetic variance in                  
neurodegenerative genes that can cause a disease process or overexpression of any of the              
pathways is linked to disease process, it is possible that drug with high anticholinergic              
properties can interact with it.  For this reason, we are studying Drug-Gene Interaction.  
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11. EXPERIMENTAL APPROACH 
11.1 CELL CULTURE EXPERIMENTS 
Normal human astrocytes (Lonza, Walkersville Inc, Walkersville, MD, USA) at pass two were             
seeded at a density of 5000 cells/cm​2 and cultured at 80% confluence in growth media (AGM-2,                
Lonza) at physiological temperature. Serum-free media (ABM-2. Lonza) was used 24 h prior to              
treatment. Cell viability was assessed by trypan blue (Sigma) staining for normal human             
astrocytes (NHA) treated with Diphenhydramine (Benadryl) 66ng/ml. All working solutions of           
Diphenhydramine were dissolved in RNA free water (Sigma). The effects of Diphenhydramine            
on MCP-1 and IL-6 proteins were observed as described below. Treatment groups included             
control (untreated), and Diphenhydramine (66ng/ml) alone. Diphenhydramine was obtained         
from Sigma-Aldrich. Each experiment was performed four times. 
 
 11.2 PROTEIN QUANTIFICATION AND GENE EXPRESSION 
MCP-1 and IL-6 protein concentrations were measured in duplicate by immunofluorescence           
detection (R&D Systems, Minneapolis, USA) and normalized to total protein content. If            
Diphenhydramine induced changes in protein concentrations, gene expression was performed.          
RNA (Ribonucleic acid) is isolated from the normal human astrocytes using the RNeasy mini kit               
(Qiagen Inc., Valencia, USA) and converted to Complementary deoxyribonucleic acid (cDNA)           
using a high capacity cDNA reverse transcription protocol (Applied Biosystems, Foster City,            
USA). RNA and cDNA quality was assessed by absorbance (Thermo Scientific™ NanoDrop™            
One). Real-time PCR (RT-PCR) was performed using primer and probe sets for the ​CACNA1C​,              
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CYP2D6​, ​GCLM​, ​GRM1​, ​GRM2 and ​CREB1 and the housekeeping gene glyceraldehyde           
3-phosphate dehydrogenase (GAPDH, Taqman Gene Expression Assays, Applied Biosystems         
Inc.) 
11.3 STATISTICAL ANALYSIS 
One-way ANOVA compared MCP-1 and IL-6 protein concentrations with Tukey correction for            
multiple corrections. The gene expression was reported with relative significance (p= 0.05)            
using Student’s t-test. 
 
12. RESULTS 
12.1 EFFECT OF DIPHENHYDRAMINE ON IL-6 AND MCP-1 PROTEIN PRODUCTION 
Diphenhydramine produces a 10% non-significant decrease in MCP-1 protein production           
(mean±SEM: 3866±49.73 pg/mg vs 3200±327.1pg/mg, p=NS). (Fig 1) In contrast,          
Diphenhydramine at doses 66ng/ml produces a statistically significant 20% decrease in IL-6            
protein (mean±SEM: 85.45±3.78 pg/mg vs 68.65±1.94, pg/mg,p=0.029). (Fig 2) 
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Fig 1: Effect of Diphenhydramine on MCP-1 protein production (​𝙥​ < 0.05 denoted by *) 
 
 
 
Fig 2: Effect of Diphenhydramine on IL-6 protein production (​𝙥​ < 0.05 denoted by *) 
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12.2 EFFECT OF DIPHENHYDRAMINE ON GRM-1 mRNA PRODUCTION 
After observing the IL-6 protein lowering effects, we tested if diphenhydramine modulated            
mRNA expression of neurocognitive genes. Diphenhydramine at doses 66 ng/ml significantly           
decreased ​GRM1 mRNA expression (Fig 3). In contrast, diphenhydramine at doses 66 ng/ml did              
not produce a significant effect on ​CACNA1C​, ​CYP2D6​, ​GCLM​, ​GRM2, and ​CREB1 mRNA             
expression (Fig 3). 
 
Fig 3: Effect of Diphenhydramine on Gene mRNA production (​𝙥​ < 0.05 denoted by *) 
13. DISCUSSION 
Diphenhydramine, a first-generation antihistamine, is commonly available to treat the rash, dry            
and itchy eyes, common cold, hay fever, and allergies. It is also evident from different reports                
that long-term usage of drugs with high anticholinergic activity such as antihistamines can             
produce cognitive impairment or decline in older adults. Anticholinergic drugs are hypothesized            
to be pro-inflammatory, but in our current experimental model of normal human astrocytes,             
diphenhydramine demonstrated an anti-inflammatory effect. In the present study, we observed           
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diphenhydramine’s effects on MCP-1 and IL-6 protein production at physiologic drug           
concentrations (66ng/ml). In this study, we found no significant reduction of diphenhydramine on             
MCP-1. Animal studies suggest that MCP-1 levels were elevated in older and young             
heterochronic parabionts, a young mouse whose vascular system is joined with an older             
mouse.​20,21 ​In a longitudinal analysis of an asymptomatic older adult cohort, increased MCP-1             
levels were associated with longitudinal decline in verbal episodic memory.​22 ​To add support to              
their findings, Lee indicated that higher baseline MCP-1 levels are related to decreased             
cognitive function over time ​23 
We observed a statistically significant reduction in IL-6 protein production. In the Rotterdam             
Study, IL-6 was found to be associated with an increased risk of dementia. Neuroimaging              
studies also demonstrated more robust associations with IL-6. In a multiethnic cohort study,             
elevated serum IL-6 levels were also associated with a global measure of cognitive function. In               
addition to this, higher levels were also found in Alzheimer’s disease patients’ spinal fluid.  
In addition to the effects on IL-6 protein levels, diphenhydramine lowered basal ​GRM1 mRNA              
expression. It is a G-protein coupled receptor for glutamate. Ligand binding causes a             
conformational change that triggers signaling via guanine nucleotide-binding proteins (G          
proteins) and modulates downstream effectors’ activity. Signaling activates a         
phosphatidylinositol-calcium second messenger system. It also participates in glutamate’s         
central action in the CNS, such as long-term potentiation in the hippocampus and long-term              
depression in the cerebellum. After CNS injuries such as trauma or ischemia or in CNS               
neurodegenerative disorders, the properties of astrocytes change, the cells become more           
reactive. Stable expression of metabotropic glutamate receptors (GRM1 and GRM5) was also            
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reported. Animal studies suggest that inherited ataxia can be associated with defective            
expression of mGlu receptors in Purkinje cells. Ataxic transgenic mice have shown mutations of              
GRM1​ gene and reduced expression of mGlu receptors ​24–26 
In conclusion, we have observed a novel anti-inflammatory effect of diphenhydramine. Further            
studies of cotreatment with IL-1b to simulate aging and characterize diphenhydramine’s effects            
on different brain cell populations are warranted. Diphenhydramine prominently reduced ​GRM1           
expression, thus potentially impacting the glutamatergic pathway. The impact of          
diphenhydramine on GRM1 mRNA expression should also be tested in additional models of             
neurocognitive diseases. 
The limitations of the studies include generating the hypothesis from ​in vitro cell culture models.               
For long-term clinical outcomes, we did not consider the impact of other therapy that could               
interact with diphenhydramine. We also did not consider additional pathogenic factors besides            
neuroinflammation. 
 
 
 
 
 
37 
 
 
14. PAROXETINE 
PAXIL (paroxetine hydrochloride) is an orally administered psychotropic drug. It is the            
hydrochloride salt of a phenylpiperidine compound identified chemically as (-)-trans-4R-(4'​          
fluorophenyl)-3S-[(3',4'-methylenedioxyphenoxy) methyl] piperidine hydrochloride hemihydrate     
and has the empirical formula of C19H20FNO3•HCl•1/2H2O. The molecular weight is 374.8            
(329.4 as a free base) ​(www.accessdata.fda.gov​) 
14.1 PHYSICOCHEMICAL PROPERTIES OF PAROXETINE HYDROCHLORIDE 
Paroxetine hydrochloride is an odorless, off-white powder with a melting point range of 120° to               
138°C and a 5.4 mg/mL solubility in water.  
14.2 PHARMACOLOGY OF PAROXETINE 
Paroxetine is a selective 5-HT reuptake inhibitor. Studies at clinically relevant doses in humans              
have shown that paroxetine blocks serotonin’s uptake into human platelets. In vitro studies in              
animals demonstrated that paroxetine is a potent and highly selective inhibitor of neuronal             
serotonin reuptake and has feeble effects on norepinephrine and dopamine neuronal reuptake.            
In vitro radioligand binding studies also indicated that paroxetine has some affinity for             
muscarinic, alpha1-, alpha2-, beta-adrenergic-, dopamine (D2)-, 5-HT1-, 5-HT2-, and histamine          
(H1)-receptors. (​www.accessdata.fda.gov​) 
14.3 PHARMACOKINETICS OF PAROXETINE 
Paroxetine is well absorbed from the gastrointestinal tract and undergoes first-pass metabolism.            
Due to its lipophilic amine character, paroxetine is extensively distributed into tissues. Its plasma              
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protein binding is about 95%. Paroxetine metabolism occurs within the liver and is mediated by               
cytochrome CYP2D6, CYP3A4, and possibly other cytochrome enzymes. Genetic         
polymorphism of CYP2D6 may alter the pharmacokinetics of paroxetine. The renal clearance of             
Paroxetine is negligible. Single-dose studies reveal that the pharmacokinetics of paroxetine is            
non-linear in most subjects. Also, steady-state pharmacokinetic parameters are not predictable           
from single-dose data. In many subjects, daily administration of 20-50mg of paroxetine leads to              
little or no disproportionality in plasma levels with dose, although this phenomenon is evident in               
a few subjects. Steady-state plasma concentrations are generally achieved within 7 to 14 days.              
The maximum plasma concentration of Paroxetine is 61.7ng/ml (​1.67*10​-4​mM) ​after 30 daily            
dose​s. The terminal half-life is about one day. In elderly subjects, there is wide interindividual               
variation in steady-state pharmacokinetic parameters, with statistically significantly higher         
plasma concentrations and slower elimination than in younger adults. ​27 
15. METHOD 
15.1 CELL CULTURE EXPERIMENTS 
Normal human astrocytes (Lonza, Walkersville Inc, Walkersville, MD, USA) at pass two were             
seeded at a density of 5000 cells/cm2 and cultured at 80% confluence in growth media (AGM-2,                
Lonza) at physiological temperature. Serum-free media (ABM-2. Lonza) was used 24 h prior to              
treatment. Cell viability was assessed by trypan blue (Sigma) staining for normal human             
astrocytes (NHA) treated with Paroxetine (​1.67*10​-4​mM)​. All working solutions of Paroxetine           
were dissolved in RNA free water (Sigma). The effects of Paroxetine on MCP-1 protein.              
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Treatment groups included control (untreated), Paroxetine (​1.67*10​-4​mM) alone, IL-1B (2ng/ml)          
and Paroxetine with IL-1B. Paroxetine was obtained from Sigma-Aldrich. 
 
 15.2 PROTEIN QUANTIFICATION AND GENE EXPRESSION 
MCP-1 was measured in duplicate by immunofluorescence detection (R&D Systems,          
Minneapolis, USA) and normalized to total protein content. If Paroxetine induced changes in             
protein concentrations, gene expression was performed. RNA (Ribonucleic acid) was isolated           
from the normal human astrocytes using the RNeasy mini kit (Qiagen Inc., Valencia, USA) and               
converted to Complementary deoxyribonucleic acid (cDNA) using a high capacity cDNA reverse            
transcription protocol (Applied Biosystems, Foster City, USA). RNA and cDNA quality was            
assessed by absorbance (Thermo Scientific™ NanoDrop™ One). Real-time PCR (RT-PCR)          
was performed using primer and probe sets for the ​CACNA1C​, ​CYP2D6​, ​CREB1, PPARG and              
the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH, Taqman Gene         
Expression Assays, Applied Biosystems Inc.) 
15.3 STATISTICAL ANALYSIS 
One-way ANOVA compared MCP-1 concentration with Tukey correction for multiple corrections.           
The gene expression was reported with relative significance (p= 0.05) using Student’s t-test. 
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16. RESULTS 
16.1 EFFECT OF PAROXETINE ON IL-1B STIMULATED MCP-1 PRODUCTION 
In basal conditions, Paroxetine at doses ​1.67*10​-4​mM ​did not produce any significant effects on              
MCP-1 production (Fig 4). Furthermore, Paroxetine did not inhibit the induction of MCP-1 by              
pro-inflammatory cytokine IL-1B (Fig 4). 
 
 ​(Fig 4: Effect of Paroxetine on IL-1B stimulated MCP-1 protein production (​𝙥​ < 0.05 denoted by *) 
 
16.2 EFFECT OF PAROXETINE ON IL-1B STIMULATED CACNA1C AND CYP2D6 mRNA           
PRODUCTION 
After investigating the impact of Paroxetine on MCP-1 protein production, we tested whether             
Paroxetine modulated basal or stimulated CACNA1C and CYP2D6 mRNA expression. In basal            
conditions, with Paroxetine at doses ​1.67*10​-4​mM, we did not see any statistically significant             
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effect. However, Paroxetine inhibits the IL-1B induced expression of ​CACNA1C (Fig 5) and             
CYP2D6​ (Fig 6).  
 
Fig 5: Effect of Paroxetine on IL1B stimulated CACNA1C mRNA expression (​𝙥​ < 0.05 denoted by *) 
 
 
Fig 6: Effect of Paroxetine on IL-1B stimulated CYP2D6 mRNA expression (​𝙥​ < 0.05 denoted by *) 
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16.3 EFFECT OF PAROXETINE ON IL-1B STIMULATED CREB 1 AND PPARG mRNA            
EXPRESSION 
We tested whether Paroxetine at physiologic drug concentration ​1.67*10​-4​mM modulated basal           
or stimulated ​CREB1 and ​PPARG mRNA expression. Under basal conditions, Paroxetine did            
not produce any significant effects. However, Paroxetine blunted IL-1B induction of ​CREB1 and             
PPARG​ (Fig 7& Fig 8). 
 
Fig 7: Effect of Paroxetine on IL-1B stimulated CREB 1 mRNA expression (​𝙥​ < 0.05 denoted by*) 
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Fig 8: Effect of Paroxetine on IL-1B stimulated PPARG mRNA expression (​𝙥​ < 0.05 denoted by*) 
 
17. DISCUSSION. 
The prevalence rate of depression in elderly rates around 10-15% for those living in the               
community. Selective Serotonin Reuptake Inhibitors, including Fluoxetine, Paroxetine,        
Citalopram, Sertraline, Escitalopram is the most prescribed type of antidepressants. In 1990,            
selective serotonin inhibitors (SSRIs) became the first treatment for depression, replacing the            
tricyclic antidepressant (TCAs). Many recent clinical ​28,29 and preclinical studies ​30–32 have            
shown that the brain’s inflammatory processes are involved in depression.  
In the current experimental model of normal human astrocytes, we examined the effects of              
Paroxetine on IL-1B stimulated production of MCP-1 at physiologic cMax concentration           
(​1.67*10​-4​mM). ​In the current study, we observed that Paroxetine does not impact inflammation             
in normal human astrocytes. Lehto et al. and Grassi-Oliveria et al. reported that depression was               
associated with lower MCP-1 concentration than healthy controls.​33,34 Myung et al.,2016           
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reported lower MCP-1 levels in a study conducted in sixty-six Korean patients with major              
depressive disorder receiving antidepressant monotherapy for six weeks (Escitalopram,         
sertraline, paroxetine, fluoxetine, and mirtazapine).​35 MCP-1 is known to attract peripheral           
monocytes to the brain, which results in an inflammatory reaction. One case-control study             
investigated the role of G-2518A polymorphism of the MCP-1 gene and found that A allele is                
associated with increased psychopathology. In a Korean population, subjects with A allele were             
found to have an increased risk of developing the major depressive disorder and psychotic              
features compared to those with the G allele. ​36 Recently it is shown that lower serum levels of                  
MCP-1 predict the lack of response of antidepressants ​37 
We also examined the effect of Paroxetine on basal and IL-1B stimulated ​CACNA1C, CYP2D6,              
CREB-1, ​and ​PPARG ​mRNA expression. We observed that Paroxetine prevents          
inflammation-induced mRNA expression of ​CACNA1C, CYP2D6, CREB-1, and PPARG. 
CACNA1C encodes for the pore-forming 1C subunit of the Ca​v​1.2 L-type calcium channel             
(LTCC). CACNA1C mediates the influx of calcium ions into the cell upon membrane             
polarization, plays an essential role in dendritic development, neuronal survival, synaptic           
plasticity, and memory/learning. 
​CACNA1C has been considered a promising candidate gene associated with psychiatric            
disorder.​38 Polymorphisms in CACNA1C gene have been recognized by Genome-wide          
association studies (GWAS) with the risk of developing schizophrenia, bipolar disorder, and            
major depressive disorder.​39–41 In healthy volunteers, risk-associated single nucleotide         
polymorphisms in CACNA1C have predicted higher scores on depression, anxiety, negative           
mood, interpersonal sensitivity. ​42,43 In rodents, the pharmacological blockade of LTCCs resulted            
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in antidepressants effect in learned helplessness paradigm and forced swim and tail suspension             
tests. ​44–46 In a large sample study conducted by Beitelshees et al, the investigators screened 46                
polymorphisms within CACNA1C to investigate associations between cardiovascular disease         
outcomes and treatment responses. They discovered that rs1051375 variant status had a            
significant interaction with antihypertensive treatment strategy.​47 
CYP2D6 is a polypeptide of 497 amino acids. Even though it accounts for only a small                
percentage of total hepatic CYP450 content, its role in drug metabolism is significant. ​48              
CYP2D6 is a major drug-metabolizing enzyme responsible for eliminating 20% clinically used            
drugs. Substrates of CYP2D6 include tricyclic antidepressants (desipramine), selective         
serotonin reuptake inhibitors (paroxetine), B blockers (metoprolol), opioid analgesics (codeine)          
and anti-cancer drugs (tamoxifen).​49 CYP2D6 mediated drug metabolism exhibits large          
inter-individual variability. Based on the urinary metabolic ratio, an individual can be classified             
as ultra-rapid metabolizer (UM), normal metabolizer (NM), intermediate metabolizer (IM) and           
poor metabolizer (PM) of CYP2D6.​50 Paroxetine plasma levels are higher in older adults. A              
double-blind, randomized trial in the elderly depressed study with Paroxetine and Nortriptyline,            
conducted by Solai et al., revealed that 66 elderly depressed patients with both antidepressants              
were found to have a significant correlation between pretreatment CYP2D6 activity and            
steady-state plasma concentration.​51 
In the current experimental model in normal human astrocytes, we examined the effects of              
Paroxetine on IL-1B stimulated CREB-1 and PPARG mRNA expression. We observed that            
Paroxetine at a physiologic drug concentration (​1.67*10​-4​mM) blunted inflammation-induced         
CREB1 and PPARG mRNA expression in normal human astrocytes. 
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CREB is a 43kDa transcriptional factor that belongs to the leucine zipper family and it is a final                  
molecular target of several signaling pathways such as c-AMP, calcium, and Ras-dependent            
kinases. CREB exists in activated phosphorylated or inactive phosphorylated forms. The           
phosphorylated CREB further binds to the CREB sequence on the DNA promoter region, and              
the transcription process then starts.​52 Nibuya reported that after chronic administration of            
fluoxetine, desipramine, and mRNA CREB levels were increased in the rat hippocampus            
region.​53  
Peroxisome proliferator-activated receptor-gamma, also known as the glitazone receptor or          
NR1C3, is a type II nuclear receptor that in humans is encoded by PPARG. PPARG is a                 
member of the nuclear hormone receptor superfamily of ligand-activated transcription factors. It            
forms a heterodimer with retinoid x receptor (RXR) to bind to specific response elements in its                
target genes’ promoter region. (genecards.org). We observed that Paroxetine at a physiologic            
drug concentration (​1.67*10​-4​mM) blunted inflammation-induced PPARG mRNA expression in         
normal human astrocytes. 
18. NORMAL HUMAN BRAIN MICROVASCULAR ENDOTHELIAL      
CELLS 
Brain microvascular endothelial cells (BMECs) are the major component of the blood-brain            
barrier, limiting the passage of soluble and cellular substrates from the blood into the brain.               
They have some unique features such as tight intercellular junctions that slow paracellular flux              
and display high electrical resistance, the absence of fenestrae and a reduced level of pinocytic               
activity, and asymmetrically localized enzymes and carrier-mediated transport systems. These          
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features distinguish them from peripheral endothelial cells (Diane et al., 1995). Alterations in             
blood-brain barrier properties can contribute to neurodegenerative and neuroinfectious         
pathogenesis and exacerbation. 
19. METHOD 
19.1 CELL CULTURE EXPERIMENT 
Human brain microvascular endothelial cells were grown in EBM-2 medium (Lonza,           
Walkersville, MD). The cells were grown at 5% CO​2​, 37 C, and 95% relative humidity and when                 
reached 90% confluency were treated with Paroxetine (​1.67*10​-4​mM​). Cell viability was           
assessed by trypan blue (Sigma) staining for normal human brain microvascular endothelial            
cells (NHBMECs) treated with Paroxetine (​1.67*10​-4​mM)​. All working solutions of Paroxetine           
were dissolved in RNA free water (Sigma). The effects of Paroxetine on MCP-1 protein was               
observed. Treatment groups included control (untreated), Paroxetine (​1.67*10​-​4​mM) alone,         
IL-1B (2ng/ml) and Paroxetine with IL-1B. Paroxetine was obtained from Sigma-Aldrich. 
 
 19.2 PROTEIN QUANTIFICATION AND GENE EXPRESSION 
MCP-1 was measured in duplicate by immunofluorescence detection (R&D Systems,          
Minneapolis, USA) and normalized to total protein content. If Paroxetine induced changes in             
protein concentrations, gene expression was assessed via RT-PCR. RNA (Ribonucleic acid)           
was isolated from the normal human brain microvascular endothelial cells using the RNeasy             
mini kit (Qiagen Inc., Valencia, USA) and converted to Complementary deoxyribonucleic acid            
(cDNA) using a high capacity cDNA reverse transcription protocol (Applied Biosystems, Foster            
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City, USA). RNA and cDNA quality was assessed by absorbance (Thermo Scientific™            
NanoDrop™ One). Real-time PCR (RT-PCR) was performed using primer and probe sets for             
the ​CCL2, CXCL5, GRM1, SOD1 and CYP2D6 ​and the housekeeping gene glyceraldehyde            
3-phosphate dehydrogenase (GAPDH, Taqman Gene Expression Assays, Applied Biosystems         
Inc.) 
19.3 STATISTICAL ANALYSIS 
One-way ANOVA compared MCP-1 concentrations with Tukey correction for multiple          
corrections. The gene expression was reported with relative significance (p= 0.05) using            
Student’s t-test. 
 
20. RESULTS 
20.1 EFFECT OF PAROXETINE ON IL-1B STIMULATED MCP-1 PRODUCTION  
In basal conditions, Paroxetine at ​1.67*10​-4​mM in normal human brain microvascular endothelial            
cells ​did not produce any effects on inflammation (Fig 9). Furthermore, Paroxetine did not inhibit               
MCP-1 induction by IL-1B (Fig 9).  
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Fig 9: Effect of Paroxetine on IL-1B stimulated MCP-1 protein production (​𝙥​ < 0.05 denoted by *) 
 
20.2 EFFECT OF PAROXETINE ON IL-1B STIMULATED CCL2 AND CXCL5 mRNA           
EXPRESSION 
We tested whether Paroxetine lowered basal or stimulated ​CCL2 and ​CXCL5 mRNA            
expression. Paroxetine at ​1.67*10​-4​mM did not produce any significant effects on basal or IL-1B              
treated normal human brain microvascular endothelial cells (Fig 10 & Fig 11). 
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Fig 10: Effect of Paroxetine on IL-1B stimulated CCL2 mRNA expression (​𝙥​ < 0.05 denoted by *) 
 
 
 
 
 
Fig 11: Effect of Paroxetine on IL-1B stimulated CXCL5 mRNA expression (​𝙥​ < 0.05 denoted by *) 
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20.3 EFFECT OF PAROXETINE ON IL-1B STIMULATED GRM-1 AND SOD1 mRNA           
EXPRESSION 
In basal or IL-1B stimulated conditions, Paroxetine at doses ​1.67*10​-4​mM did not produce any              
significant effects on ​GRM-1 in normal human brain microvascular endothelial cells (Fig 12).             
However, basal Paroxetine treatment induced the expression of ​SOD-1​(Fig 13). 
 
 
Fig 12: Effect of Paroxetine on IL-1B stimulated GRM1 mRNA expression (​𝙥​ < 0.05 denoted by *) 
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Fig 13: Effect of Paroxetine on IL-1B stimulated SOD1 mRNA expression (​𝙥​ < 0.05 denoted by *) 
 
20.4 EFFECT OF PAROXETINE ON IL-1B STIMULATED CYP2D6 mRNA EXPRESSION 
In basal conditions, Paroxetine at ​1.67*10​-4​mM did not produce any significant effects on             
CYP2D6 ​expression in normal human brain microvascular endothelial cells. However,          
Paroxetine prevents IL-1B induced ​CYP2D6 mRNA expression in normal human brain           
microvascular endothelial cells (Fig 14). 
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Fig 14: Effect of Paroxetine on IL-1B stimulated CYP2D6 mRNA expression (​𝙥​ < 0.05 denoted by *) 
 
21. DISCUSSION 
In the current experimental model of normal human brain microvascular endothelial cells, we             
examined the effects of Paroxetine on IL-1B stimulated production of MCP-1 at a physiologic              
drug concentration (​1.67*10​-4​mM). ​In the current study, we observed that Paroxetine does not             
impact inflammation in normal human brain microvascular endothelial cells, similar to what we             
saw with normal human astrocytes. We noted that Paroxetine prevents inflammation-induced           
CYP2D6 mRNA expression similar to what we found in normal human astrocytes. Furthermore,             
Paroxetine induced the expression of ​SOD1 ​in the current experimental model of normal human              
brain microvascular endothelial cells. 
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SOD1 or Cu/Zn superoxide dismutase is a soluble protein that converts harmful superoxide             
radicals to molecular oxygen and hydrogen peroxide. The human SOD1 gene located on             
chromosome 21q22.11and codes for monomeric SOD1 polypeptide. SOD1 expression studies          
still produce conflicting data about whether increased or inhibited regulation is harmful.​54,55 
In a study conducted, ​SOD1 gene expression was elevated in specific nervous systems             
(brainstem and spinal cord), commonly affected by Amyotrophic Lateral Sclerosis but not in             
other brain regions (cerebellum and cerebral cortex) affected during neurodegenerative          
processes. ​56 
Further studies of cotreatment with IL-1b to simulate aging, and also to characterize the              
paroxetine effects on different populations of brain cells are warranted. The impact of paroxetine              
to induce the expression of SOD1 mRNA expression should also be examined in additional              
models of neurocognitive diseases. 
The limitations of the studies include generating the hypothesis from in-vitro cell culture models.              
For long-term clinical outcomes, we did not consider the impact of other therapy that could               
interact with paroxetine. We also did not consider additional pathogenic factors besides            
neuroinflammation. 
OVERALL CONCLUSIONS 
We did not observe a shared biologically plausible pathway shared between the anticholinergic             
drugs that we examined (i.e., pro-inflammatory cascade). Therefore, Comprehensive         
approaches that examine the pharmacologic properties of anticholinergic drugs within the aging            
brain are warranted.  
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